September 5, 2019 07:07 AM EDTUpdated 09:26 AM
Pharma

Mallinck­rodt preps a pos­si­ble bank­rupt­cy amid a mael­strom of opi­oid claims — re­port

John Carroll

Editor & Founder

Strug­gling with $5 bil­lion in debt and a mael­strom of le­gal claims over their al­leged role in a na­tion­wide epi­dem­ic of opi­oid abuse, Mallinck­rodt has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times